Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Welcome Back! We’ve Missed You!
WELCOME BACK! WE’VE MISSED YOU! Inside this Special Research Edition of the Spring 2021 CMTA Report, we bring you coverage of every aspect of CMTA-STAR from cross-type initiatives to our…
A New Treatment for CMT1A
…CMT research and clinical trials such as this one, please complete a Patients as Partners in Research profile and support the CMTA’s mission to develop treatments for CMT. Published on:…
How to Contact Your Hometown Media
…their work. The CMTA launched the Strategy to Accelerate Research, or CMTA-STAR, in 2008 to capitalize on breakthroughs in genetics and dramatically speed up the pace of CMT research. Since…
Giant Axonal Neuropathy (GAN)
…removed and examined to look for swollen axons). A definitive diagnosis using genetic testing is available on a research basis only. What research is being done around GAN? Charcot-Marie-Tooth Association,…
Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
…the CMTA’s research efforts are consolidated under the banner of STAR—which brings together the world’s largest network of biotech research partners, research scientists, clinicians and patients—and funds more CMT grants…
2021 STAR Accomplishments
With our community’s help, the CMTA has invested over $17.5 million in CMTA-STAR research since 2008, making us the largest charitable funder of CMT research globally. Through the support of…
The CMTA Earns a Perfect Rating From Charity Navigator
…million people worldwide. About The Charcot-Marie-Tooth Association The CMTA is the largest philanthropic funder of CMT research worldwide. The CMTA’s Strategy to Accelerate Research (STAR) brings the best CMT researchers,…
Novartis Secures $1.3B Deal for CMT Treatment CKD-510
…portfolio. The significance of this collaboration is underscored by the substantial financial investment and the broader landscape of CMT research. HDAC6 has long been a focal point of CMT research,…
CMTA Hails Novartis Acquisition of DTx Pharma And Its CMT1A Therapeutic Program
…Baloh, MD, PhD, global head of neuroscience for the Novartis Institutes for BioMedical Research, said the acquisition “underscores the Novartis commitment to bringing life-changing medicines forward for patients with neuromuscular…
CMTA Funds Preclinical Work on Modulating Unfolded Protein Response in CMT1B Mice
…largest philanthropic funder of CMT research worldwide. The CMTA’s Strategy to Accelerate Research (STAR) brings the best CMT researchers, clinicians, and experts in therapy development together with pharmaceutical and biotechnology…